Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Abstract
Retroperitoneal liposarcomas are a rare entity and are comprised mostly of the well-differentiated and dedifferentiated subtypes. Eight-year survival ranges from 30% to 80% depending on histologic subtype and grade. Surgery is the cornerstone of treatment and compartment resection is the current standard. Mesenteric liposarcomas are extremely rare and comprise more high-grade lesions, with poorer prognosis of 50% 5-year overall survival. They are managed with a similar aggressive surgical approach. This review presents the current management of retroperitoneal and mesenteric liposarcomas.Citation
Siew CCH, Apte SS, Baia M, Gyorki DE, Ford S, van Houdt WJ. Retroperitoneal and Mesenteric Liposarcomas. Surg Oncol Clin N Am. 2022 Jul;31(3):399-417. doi: 10.1016/j.soc.2022.03.005Type
ArticleAdditional Links
http://www.sciencedirect.com/science/journal/10553207PMID
35715141Publisher
Elsevierae974a485f413a2113503eed53cd6c53
10.1016/j.soc.2022.03.005